Xmetix
Smart Tactical Garments
Startup Seed Aerospace, Defense & HLS Est. 2019
Total Raised
Undisclosed
Seed
Last Round
Undisclosed
2 rounds
Investors
2
2 public
Team
7
1-10 employees
Confidence
97/100
Patents
1
About
Xmetix is revolutionizing battlefield and emergency medicine with the TAK710, the world’s first fully automated tourniquet. Designed for military, first responders, and civilian use, TAK710 eliminates human error in life-threatening bleeding control with one-button activation, precise pressure control, and extended stabilization capabilities. Xmetix’s proprietary technology, backed by multiple patents, ensures rapid, reliable, and adjustable hemorrhage control, reducing blood loss, improving survival rates, and optimizing long-term patient outcomes. Already in use by elite military units, TAK710 is poised to become the new standard in tactical medicine.
Classification
Sector
Aerospace, Defense & HLSDefense & HLS SolutionsCombat Equipment & SystemsHealth Tech & Life Sciences
Core Technology
Machinery & Robotics
Target Customer
Defense, Safety & SecurityNational SecurityMilitarySecurityPublic SecurityLaw EnforcementHomeland Security
Business Model
B2GB2BB2B2C
Tags
homeland-securitydual-usepoliceemergency-responsedefensemedical-technologieslaw-enforcementtactical-gearmedical-devices
Funding & Events
Oct 2024
Seed Undisclosed
NGT HealthCare II
Jun 2020
Undisclosed Round Undisclosed
NGT3
Details
Product Stage
Released
Employees
1-10
Exact Count
9
District
North District
Founded
2019
Registrar
516185105
Locations
Wadi el-Haj Street 13, Nazareth, Israel
Links
Website
LinkedIn
Admin
Last Update
Mar 12, 2025
Verified by
Jenny Sotnik-Talisman
Claimed
Yes
Missing
video or image, news, markets
Team (7)
Leonardo Schwarts
CEO
Irad Kuhnreich
Co-founder & CEO
Founder
Barak Ranon
Xmetix USA CEO
Eviatar Kuhnreich
Co-founder & Clinical lead
Founder
Pablo Ocumpo
COO
Amir Fabian
R@D manager
Anat Artzi
Suply Chain manager
Internal
Created by
Jenny Sotnik-Talisman (genys30@yahoo.com)
Created
2019-05-02T00:00:00.000Z
Last editor
Jenny Sotnik-Talisman (genys30@yahoo.com)